Nasasinuspray Sine Conservans (Xylometazoline Hydrochloride)

Xylometazoline, the active ingredient in Nasasinuspray Sine Conservans, is an alpha-adrenergic agonist presented as a nasal spray for nasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis in adults and children.

GNH USA supplies Nasasinuspray Sine Conservans as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline is indicated for nasal congestion caused by conditions that involve inflammation of the nasal mucosa. - Common cold: reduces nasal blockage and improves airflow. - Sinusitis: alleviates congestion and facilitates sinus drainage. - Allergic rhinitis: diminishes swelling of nasal passages and eases breathing.

Xylometazoline nasal spray may cause local and systemic adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing. - Headache. - Altered taste perception.

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis. - Cardiac arrhythmias. - Nasal ulceration or tissue necrosis. - Allergic reactions including anaphylaxis. - Rebound congestion (rhinitis medicamentosa) after prolonged use. - Vision disturbances.

Before using Xylometazoline nasal spray, consider the following precautions. - Use in children under 6 years: not recommended unless directed by a physician. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Concurrent use with monoamine oxidase inhibitors: may increase risk of hypertensive events. - Prolonged use beyond 3 days: may cause rebound congestion. - Avoid in patients with severe hypertension or coronary artery disease. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Xylometazoline may interact with other medicines; review the following.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other nasal decongestants: additive vasoconstriction leading to hypertension. - Systemic sympathomimetics (e.g., pseudoephedrine): increased cardiovascular effects.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: may reduce efficacy of blood pressure control. - Beta‑blockers: potential for altered heart rate response. - Tricyclic antidepressants: possible additive sympathomimetic activity.